{"analyses":[{"ciLowerLimit":"-6.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.63","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8757","paramType":"Difference in ORR","paramValue":"0.54","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"17.3","value":"10.5"},{"groupId":"OG001","lowerLimit":"7.4","upperLimit":"15.6","value":"11.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"245"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1). CR was defined as the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \\< 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD in the absence of CR. Percentage of participants who achieved confirmed objective response (CR or PR) have been reported. Percentages have been rounded to one decimal place.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg"},{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"NUMBER","populationDescription":"Response-evaluable population included all participants with measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"Up to approximately 25 months","title":"Part 2: Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}